Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19176483 | 0.96 | RXRA (0.33) | RXRARXRBRXRGZDHHC20 | |
| SCHEMBL24690506 | 0.94 | RXRA (0.33) | RXRARXRBRXRGZDHHC20 | |
| SCHEMBL19801129 | 0.91 | NPC1 (0.31) | RXRARXRBRXRGNPC1L3MBTL1 | |
| SCHEMBL21166373 | 0.89 | RXRA (0.34) | RXRARXRBRXRGZDHHC20 | |
| SCHEMBL18737544 | 0.88 | RXRA (0.34) | RXRARXRBRXRGZDHHC20NPC1 | |
| SCHEMBL18999618 | 0.88 | RXRA (0.34) | RXRARXRBRXRGZDHHC20NPC1 | |
| SCHEMBL18431662 | 0.88 | NPC1 (0.33) | RXRARXRBRXRGNPC1L3MBTL1 | |
| SCHEMBL22420051 | 0.86 | RXRA (0.35) | RXRARXRBRXRG | |
| SCHEMBL22039955 | 0.85 | RXRA (0.36) | RXRARXRBRXRG | |
| SCHEMBL19069345 | 0.85 | RXRA (0.33) | RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774052-B2 | Heteroaryl compounds and uses thereof | CELGENE CAR LLC (BM) | 2020-09-15 | — | — | US | disclosed |
| US-10618902-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases | CELGENE CAR LLC (BM) | 2020-04-14 | — | — | US | disclosed |
| US-20190218220-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218220-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | PRKACA, PRKDC, AURKC | RXRA 3816/4885RXRB 3600/4885RXRG 3593/4885 |
| US-10774052-B2 | Heteroaryl compounds and uses thereof | ABCG2, CYP3A43, CYP3A5 | RXRA 1018/4885RXRB 949/4885RXRG 1099/4885 |
| US-10618902-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases | PDXK, DCK, DTYMK | RXRA 3722/4885RXRB 3259/4885RXRG 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.